Nielsen, 28, was diagnosed with MS aged 17 and initially believed that her athletics dreams were over due to her lack of ...
Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Fate ...
Sanofi announces update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study: Paris Friday, February 14, 2025, 12:00 Hrs [IST] A scheduled review of the E.mbrace p ...
22h
Hosted on MSNSanofi Ends E.coli Vaccine Trial Amid Efficacy ConcernsSanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...
Filing of the 2024 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report ...
Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, 13, 2025. Sanofi announces today the filing of its Form 20-F with the U ...
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...
French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine ...
Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results